- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/36 - Opioid-abuse
Patent holdings for IPC class A61P 25/36
Total number of patents in this class: 724
10-year publication summary
|
30
|
23
|
51
|
72
|
73
|
71
|
57
|
88
|
58
|
20
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Indivior UK Limited | 193 |
14 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2837 |
14 |
| Taisho Pharmaceutical Co., Ltd. | 859 |
12 |
| Intra-Cellular Therapies, Inc. | 407 |
11 |
| Guangxi Jiufu Biotechnology Co., Ltd | 13 |
11 |
| University of Florida Research Foundation, Inc. | 3983 |
9 |
| Altria Client Services LLC | 2171 |
8 |
| Virginia Commonwealth University | 621 |
8 |
| The Regents of the University of California | 19803 |
7 |
| Banyu Pharmaceutical Co., Ltd. | 75 |
7 |
| University of Kentucky Research Foundation | 684 |
7 |
| Kinoxis Therapeutics Pty Ltd | 18 |
7 |
| Hoffmann-La Roche Inc. | 3369 |
6 |
| Takeda Pharmaceutical Company Limited | 2703 |
6 |
| Demerx, Inc. | 74 |
6 |
| Hikma Pharmaceuticals USA Inc. | 161 |
6 |
| Alar Pharmaceuticals Inc. | 12 |
6 |
| Novartis AG | 10927 |
5 |
| The Trustees of Columbia University in the City of New York | 3558 |
5 |
| Astellas Pharma Inc. | 1085 |
5 |
| Other owners | 564 |